Skip to main
JSPR
JSPR logo

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

Jasper Therapeutics (JSPR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Jasper Therapeutics Inc is positioned favorably within the biotechnology sector due to its innovative focus on hematopoietic stem cell therapies and the development of safer conditioning agents. The company has demonstrated a compelling efficacy profile, with a notable 89% complete response (CR) rate observed in clinical trials, highlighting the potential effectiveness of its treatments. Additionally, Jasper's briquilimab is distinguished by its shorter half-life, which could enhance its therapeutic applications compared to competition, suggesting a robust pipeline that may drive future growth.

Bears say

Jasper Therapeutics Inc has faced significant setbacks, including a nearly 5% decline in stock price, attributed to an investigation into a faulty drug lot for briquilimab, which has also led to a pause in the ETESIAN trial for asthma. Additionally, the company raised $30 million through common stock and pre-funded warrants, suggesting potential liquidity challenges amidst ongoing operational issues. The reduction of the price target from $20 to $7 further reflects a negative outlook, underscoring concerns about the company's current financial health and future growth prospects.

Jasper Therapeutics (JSPR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Jasper Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Jasper Therapeutics (JSPR) Forecast

Analysts have given Jasper Therapeutics (JSPR) a Buy based on their latest research and market trends.

According to 8 analysts, Jasper Therapeutics (JSPR) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Jasper Therapeutics (JSPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.